Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantAetna hematopoietic cell transplant Coverage Updat…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0617

    Hematopoietic Cell Transplantation for Testicular Cancer

    Customize your policy alerts

    Sign up for Aetna Policy 0617 alerts

    Get alerted when Policy 0617 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Aetna's clinical policy bulletin defining medical necessity criteria for hematopoietic cell transplantation (primarily autologous) in persons with testicular cancer, and listing procedures considered experimental/investigational (including allogeneic transplants and autologous as initial therapy).

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Testicular Cancer
    Policy CodePolicy 0617
    Change TypeNo material change
    Effective DateMay 14, 2002
    Last ReviewSep 11, 2023
    Next Review DateJul 11, 2024
    Key ActionProviders must ensure that autologous (including tandem) transplantation meets the specified medical necessity criteria (refractory disease defined as <50% tumor reduction; partial response defined as >=50% reduction; relapse after standard-dose chemotherapy) to qualify for coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Covered indications
    2Uncovered/experimental
    3Covered code groups

    Coverage Summary

    Scope: Aetna's Clinical Policy Bulletin (Number 0617) defines medical necessity criteria for hematopoietic cell transplantation in persons with testicular cancer, focusing primarily on autologous approaches (including tandem/autologous consolidation) and specifying procedures considered experimental/investigational. Coverage stance: mixed (some autologous transplants covered when criteria met; other approaches not covered). Status/current: CURRENT.

    Thresholds and Quick Facts
    Threshold (tumor burden) - refractory< 50% reduction
    Threshold (tumor burden) - partial response>= 50% reduction
    Effective date2002-05-14
    Last review2023-09-11
    Next review2024-07-11
    Evidence highlight - durable remissions (range)10-25% in refractory disease (some series report 20-50% CR/PR post-ASCT)
    Evidence highlight - systematic review recommendationMinimum of 2 HDCT cycles with ASCT suggested as standard for relapsed/refractory germ cell cancer

    Medical-Necessity Criteria

    Medically Necessary

    Aetna considers the following types of hematopoietic cell transplantations medically necessary for testicular cancer when criteria are met:

    Medically Necessary criteria

    • Autologous HCT for refractory or partial responders: Autologous hematopoietic cell transplantation for the treatment of persons with testicular cancer who do not attain a complete remission after an initial course of standard-dose chemotherapy, i.e., those with refractory (less than 50% reduction in tumor burden) testicular cancer or those exhibiting a partial response (at least a 50% reduction in tumor burden).refractory: <50% reduction; partial response: >=50% reduction
    • Autologous HCT as consolidation for relapse: Autologous hematopoietic cell transplantation as consolidation therapy for persons with testicular cancer who relapse after an initial course of standard-dose chemotherapy.

    Not Covered / Experimental Approaches

    Non-coverage callout: Autologous hematopoietic cell transplantation used as initial treatment instead of standard‑dose chemotherapy is considered experimental/investigational and is not covered. Similarly, allogeneic hematopoietic cell transplantation for testicular cancer is considered experimental/investigational and is not covered because effectiveness has not been established.

    Coding

    CPT codes covered if selection criteria are metCPTCovered
    38206-38230Bone marrow or stem cell services/procedures (except allogenic).
    38241Hematopoietic progenitor cell (HPC); autologous transplantation.
    96401-96549Chemotherapy administration.
    CPT codes NOT covered for indications listed in the CPBCPTNot Covered
    38205Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogenic.
    38230Bone marrow harvesting for transplantation; allogenic.
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
    HCPCS codes covered if selection criteria are metHCPCSCovered
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    C62.00-C62.92Malignant neoplasm of testis.
    D07.69Carcinoma in situ of other male genital organs [testis].

    Provider Actions

    Prior Authorization

    Selection criteria required for coverage

    Providers must ensure that autologous (including tandem) transplantation meets the specified medical necessity criteria to qualify for coverage: refractory disease defined as <50% tumor reduction; partial response defined as ≥50% reduction; or relapse after an initial course of standard-dose chemotherapy.

    • Affected codes: 38206-38230, 38241, S2150
    • Selection criteria summary: refractory (less than 50% reduction in tumor burden); partial response (at least 50% reduction in tumor burden); relapse after standard‑dose chemotherapy
    Denial Risk

    Requests for excluded procedures will be denied

    Requests for the following procedures will be denied as experimental/investigational or not covered for the indications in this policy: autologous transplantation as initial therapy instead of standard‑dose chemotherapy, and allogeneic hematopoietic cell transplantation for testicular cancer.

    Background & Evidence

    Background: Testicular germ cell tumors (seminomas and non-seminomas) typically affect men aged ~20–40 and are staged I–III based on local and metastatic spread. First-line treatment for advanced disease is cisplatin‑based combination chemotherapy (commonly cisplatin, bleomycin, etoposide for 3–4 cycles), often followed by surgery for residual masses. Salvage regimens for relapsed disease include cisplatin plus ifosfamide with etoposide or vinblastine. For relapsed or refractory disease, high‑dose chemotherapy with autologous stem cell transplantation (ASCT/ABMT), including tandem ASCT approaches, has been used and multiple series and reviews report durable remissions (reported CR rates and durable remissions in select refractory patients and pooled data supporting use of ≥2 HDCT cycles with ASCT in relapsed/refractory germ cell cancer).

    Evidence Highlights
    Reported durable complete remissions with high-dose chemo + ABMT10-25% in refractory disease; some studies report 20-50% CR/PR post-ASCT in select series
    Systematic review conclusion (Bin Riaz 2018)Pooled data suggest a minimum of 2 HDCT cycles with ASCT should be standard for relapsed/refractory germ cell cancer; failure of HDCT leads to poor prognosis with ~10% lasting remission with salvage therapy

    Revision History

    2002-05-14Effective

    Policy became effective.

    2023-09-11Last ReviewLatest

    Policy last reviewed and updated.

    2024-07-11Next Review

    Scheduled next policy review date.

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Testicular Cancer
    Policy CodePolicy 0617
    Change TypeNo material change
    Effective DateMay 14, 2002
    Last ReviewSep 11, 2023
    Next Review DateJul 11, 2024
    Key ActionProviders must ensure that autologous (including tandem) transplantation meets the specified medical necessity criteria (refractory disease defined as <50% tumor reduction; partial response defined as >=50% reduction; relapse after standard-dose chemotherapy) to qualify for coverage.
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaNot Covered / Experimental ApproachesCodingProvider ActionsBackground & EvidenceRevision History
    Tandem autologous HCT for relapsed disease:
    Tandem autologous hematopoietic cell transplantation for persons with testicular cancer who have relapsed.

    Experimental and Investigational (Not Covered)

    The following are considered experimental and investigational because effectiveness has not been established:

    Experimental and Investigational exclusions

    • Autologous HCT as initial therapy (Not Covered): Autologous hematopoietic cell transplantation as initial treatment (i.e., instead of an initial course of standard-dose chemotherapy with Food and Drug Administration-approved drugs) of persons with testicular cancer.

      Not covered - effectiveness not established.

    • Allogeneic HCT (Not Covered): Allogeneic hematopoietic cell transplantation for the treatment of persons with testicular cancer.

      Not covered - effectiveness not established.

    • Excluded procedure codes: 38205, 38230, 38240
    • Note: Autologous transplantation as initial therapy and allogeneic hematopoietic cell transplantation are considered experimental/investigational and are not covered.